<?xml version="1.0" encoding="UTF-8"?>
<p>Raltegravir (RAL), the first approved HIV integrase inhibitor, has potent activity against both HIV-1 and HIV-2, and also retains activity against viruses that have become resistant to antiretroviral agents of other classes because of its unique mechanism of action [
 <xref rid="B81-pharmaceutics-12-00171" ref-type="bibr">81</xref>,
 <xref rid="B82-pharmaceutics-12-00171" ref-type="bibr">82</xref>,
 <xref rid="B83-pharmaceutics-12-00171" ref-type="bibr">83</xref>,
 <xref rid="B84-pharmaceutics-12-00171" ref-type="bibr">84</xref>]. RAL was encapsulated into a polymeric PLGA nano-formulation and gold nanoparticles (see 
 <xref rid="pharmaceutics-12-00171-t002" ref-type="table">Table 2</xref>).
</p>
